التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
AbbVie Inc
Closed
Sector Healthcare
164.93 -2.74
Overview
Share price change
24h
Min
164.91
Max
166.05
Income | 191M 1.6B |
|---|---|
Sales | 14B |
P/E Sector Avg | 51.05 94.998 |
EPS | 3 |
Dividend yield | 3.14 |
Profit margin | 10.795 |
Employees | 50,000 |
EBITDA | 1B 6B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +25.12 upside |
Dividend yield Sector Avg | 3.14% 2.40% |
|---|---|
Next Earnings | ٣١ يناير ٢٠٢٥ |
Next Dividend date | ١٣ فبراير ٢٠٢٥ |
Next Ex Dividend date | ١٣ يناير ٢٠٢٥ |
Market Cap | -66B 296B |
|---|---|
Previous open | 167.67 |
Previous close | 164.93 |
News Sentiment
By Acuity
36%
64%
125 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
AbbVie Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AbbVie Inc Forecast
Price Target
By TipRanks
25.12% upside
12 Months Forecast
Average 206.44 USD 25.12%
High 240 USD
Low 165 USD
Based on 20 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.
Sentiment
By Acuity
125 / 392 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AbbVie Inc
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
